OLD Second National Bank of Aurora Lowers Stock Position in Johnson & Johnson $JNJ

OLD Second National Bank of Aurora cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 29,245 shares of the company’s stock after selling 663 shares during the period. Johnson & Johnson accounts for approximately 1.0% of OLD Second National Bank of Aurora’s holdings, making the stock its 26th biggest holding. OLD Second National Bank of Aurora’s holdings in Johnson & Johnson were worth $4,467,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in JNJ. Brighton Jones LLC grew its stake in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the period. Wealth Group Ltd. purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at $218,000. Signal Advisors Wealth LLC lifted its holdings in shares of Johnson & Johnson by 7.1% during the 1st quarter. Signal Advisors Wealth LLC now owns 8,531 shares of the company’s stock valued at $1,415,000 after acquiring an additional 562 shares in the last quarter. Procyon Advisors LLC lifted its holdings in shares of Johnson & Johnson by 14.6% during the 1st quarter. Procyon Advisors LLC now owns 62,994 shares of the company’s stock valued at $10,300,000 after acquiring an additional 8,048 shares in the last quarter. Finally, Prospect Financial Services LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter valued at $268,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on JNJ. UBS Group set a $198.00 target price on shares of Johnson & Johnson in a report on Friday. The Goldman Sachs Group lifted their target price on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a report on Friday, September 19th. Barclays lifted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Johnson & Johnson in a report on Saturday, September 27th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $188.88.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $188.51 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $189.78. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market capitalization of $453.98 billion, a P/E ratio of 20.16, a P/E/G ratio of 2.40 and a beta of 0.40. The company’s fifty day moving average price is $176.18 and its two-hundred day moving average price is $162.83.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is 55.61%.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.